FdaApplication
BLA 125816
Identifiers
- fda_app_no: BLA125816
Properties
| Property | Value |
|---|---|
| applicant_name | Axogen Corporation |
| application_type | BLA |
| approval_date | 2025-12-03 |
Revenue by product
AVANCE NERVE GRAFT
| Period | Revenue |
|---|---|
| Q2 2026 | $69.7M† |
| Q1 2026 | $61.5M† |
| Q4 2025 | $59.9M† |
| Q3 2025 | $60.1M† |
| Q2 2025 | $56.7M† |
| Q1 2025 | $48.6M† |
| Q4 2024 | $49.4M† |
| Q3 2024 | $48.6M† |
| Q2 2024 | $47.9M† |
| Q1 2024 | $41.4M† |
| Q4 2023 | $42.9M† |
| Q3 2023 | $41.3M† |
| Q2 2023 | $38.2M† |
| Q1 2023 | $36.7M† |
| Q4 2022 | $36.2M† |
| Q3 2022 | $37.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| AVANCE NERVE GRAFT | — | 1 LENGTHS: 15 MM, 30 MM, 50 MM, AND 70 MM DIAMETERS: 1 TO 2 MM, 2 TO 3 MM, 3 | Implant |
1 product